EMBC
Embecta Corp.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $161.8M | Six months ended March 31, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 33.5% | Six months ended March 31, 2026 | — |
|
|
|||
| Adjusted gross profit non-GAAP | $131.8M | Q2 FY2026 | — |
| Adjusted gross profit margin non-GAAP | 59.4% | Q2 FY2026 | — |
|
|
|||
| Adjusted operating income non-GAAP | $48.6M | Q2 FY2026 | — |
| Adjusted operating income margin non-GAAP | 21.9% | Q2 FY2026 | — |
| Quarterly cash dividend per share | $0.01 | Q2 FY2026 | — |
| Share repurchase program authorization | $100M | Q2 FY2026 | — |
| embecta labeled products share of revenue | 75% | Q2 FY2026 call | — |
| Adjusted operating margin non-GAAP | 30.4% | Q1 FY2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EMBC
this stock
Embecta Corp.
|
$199.93M | -71.2% | -3.8% | 1.8 | 11.7% |
|
ISRG
Intuitive Surgical Inc
|
$147.01B | -24.6% | +20.5% | 50.4 | 2.2% |
|
MDLN
Medline Inc.
|
$52.94B | -4.0% | +11.5% | — | 2.1% |
|
BDX
Becton Dickinson & Co
|
$41.49B | +3.8% | +8.2% | 57.2 | 2.6% |
|
ALC
Alcon Inc
|
$32.61B | -15.2% | — | — | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EMBC | +1.8% | -0.3% | -73.4% | +3.4% | -71.2% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +0.9% | -1.7% | -81.0% | +3.2% | -80.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.